New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids

• Published in: Actanaturae 2009-07, Vol.1 (2), p.44-60
• Main Authors: Patutina, O A, Mironova, N L, Vlassov, V V, Zenkova, M A
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2075-8251
• DOI: 10.32607/20758251-2009-1-2-44-60

Currently, the main way to fight cancer is still chemotherapy. This method of treatment is at the height of its capacity, so, setting aside the need for further improvements in traditional treatments for neoplasia, it is vital to develop now approaches toward treating malignant tumors. This paper reviews innovational experimental approaches to treating malignant malformations based on the use of gene-targeted drugs, such as antisense oligonucleotides (asON), small interfering RNA (siRNA), ribozymes, and DNAzymes, which can all inhibit oncogene expression. The target genes for these drugs are thoroughly characterized, and the main results from pre-clinical and first-step clinical trials of these drugs are presented. It is shown that the gene-targeted oligonucleotides show considerable variations in their effect on tumor tissue, depending on the target gene in question. The effects range from slowing and stopping the proliferation of tumor cells to suppressing their invasive capabilities. Despite their similarity, not all the antisense drugs targeting the same region of the mRNA of the target-gene were equally effective. The result is determined by the combination of the drug type used and the region of the target-gene mRNA that it complements.